In the age of immunomodulatory agents, proteasome inhibitors, and other novel agents for the treatment of multiple myeloma (MM), the role of autologous hematopoietic stem cell transplantation (ASCT) has become an area of debate. Whereas most oncologists recognize a role for ASCT in the up-front treatment of MM, this view is not universally shared, particularly when it comes to treating younger patients with MM (<65 years old). Comorbidities were cited in a recent survey of perceptions and practices of oncologists and transplant specialists as the most frequent reason younger patients with a clinical indication for ASCT would not be referred to a transplant specialist. Although advanced age and comorbidities can limit eligibility for ASCT, these concerns are not absolute contraindications for ASCT. The use of plerixafor and captisol-enabled melphalan are advancing the limits of what can be achieved by ASCT in patients with MM.
This activity is a web-based, on-demand activity, featuring an expert panel discussion. This activity is designed as a forum for the debate and evaluation of the most recent clinical data, and to provide evidence-based updates and expert insights on the discussion points to translate current and emerging evidence into real-world clinical practice.
After finishing Part 1 of this activity, please complete Part 2.